From the operational update:
Novartis intends to initiate a Phase 3 study in non-COVID-19-related ARDS after the anticipated
closing of the license agreement and successful completion and outcome of the current study.
MSB Trading 2020 - a new dawn, page-10445
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |